Gregory Eschenauer, PharmD
Gregory Eschenauer is a Clinical Associate Professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy and clinical pharmacy specialist in infectious diseases at Michigan Medicine. Dr. Eschenauer received his Doctor of Pharmacy from Butler University and completed his pharmacy practice and infectious diseases specialty residencies at the University of Michigan. Since completing his residency, Dr. Eschenauer served as an infectious diseases clinical pharmacist at New York Presbyterian Hospital and the University of Pittsburgh Medical Center prior to joining the University of Michigan. He is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Infectious Diseases.
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Lauring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020
Tran N, Mills JP, Zimmerman C, Gandhi TN, Tribble AC, Petty LA, Nagel J, Brancaccio A, Scappaticci G, Patel T, Dillman NO, Regal R, Klein KC, Washer L, Marshall VD, Sweeney J, Rao K, Eschenauer GA. Incorporating Preauthorization into Antimicrobial Stewardship Pharmacist Workflow Reduces Clostridioides difficile and Gastrointestinal Panel Testing. Infect Control Hosp Epidemiol 2020;41:1136- 1141.
Eschenauer GA, Xiao L, Waites KB, Crabb DM, Ratliff AE, Gandhi TN, Riddell J IV, Kaul DR. Macrolide-resistant Mycoplasma pneumoniae pneumonia in transplantation: increasingly typical? Transplant Infect Dis 2020;22:e13318.
Lew AK, Crass RL, Eschenauer G. Evolution of Equations for Estimating Renal Function and Their Application to the Dosing of New Antimicrobials. Ann Pharmacother 2020;54:496- 503.
Eschenauer G, Carver P, Patel T, Lin SW, Klinker K, Pai M, Lam S. Survival in Patients with Candida glabrata Bloodstream Infections is Associated with Fluconazole Dose. Antimicrob Agents Chemother 2018;62:e02566-17.
Patel T, Carver P, Eschenauer GA. Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?" J Clin Microbiol 2018;56:e01072-18.
Welch HK, Nagel JL, Patel TS, Tandhi TN, Chen B, De Leon J, Chenoweth CE, Washer LL, Rao K, Eschenauer GA. Effect of an Antimicrobial Stewardship Intervention on Outcomes for Patients with Clostridium difficile Infection. Am J Infect Control 2016;44:1539-1543.
Carver PL, Eschenauer GA, Stuckey L, Patel T. Antifungal Prophylaxis in Lung Transplant Recipients. Transplantation 2016;100:1815-1826.
Eschenauer GA, Kwak EJ, Potoski BA, Clarke LG, Shields RK, Abdel-Massih R, Silveira FP, Vergidis P, Clancy CJ, Nguyen MH. Targeted versus Universal Antifungal Prophylaxis among Liver Transplant Recipients. Am J Transplant 2015;15:180-9.
Eschenauer GA, Nguyen MH, Clancy CJ. Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. Ann Pharmacotherapy 2015;49:1068-1074.
Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. Real-world experience with echinocandin MICs against Candida species: A multi-center study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 2014;58:1897-906
Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields RK, Clancy CJ, Nguyen MH, Lam SW. Fluconazole versus echinocandin for Candida glabrata fungemia: A retrospective cohort study. J Antimicrob Chemother 2013;68:922-926.
Eschenauer GA, Carver PL. The evolving role of antifungal susceptibility testing. Pharmacotherapy 2013;33:465-475.
Eschenauer GA, Lam SW, Carver PL. Antifungal prophylaxis in liver transplant recipients. Liver Transpl 2009;15:842- 858.
Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the intensive care unit. Crit Care Med 2009;37:1580- 1593.